Direxion Daily Healthcare Bull 3X Shares (CURE) Stock Price, News & Analysis

Company Overview

Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 44,500 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CURE Stock Analysis - Frequently Asked Questions

How do I buy shares of Direxion Daily Healthcare Bull 3X Shares?

Shares of CURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Direxion Daily Healthcare Bull 3X Shares own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Direxion Daily Healthcare Bull 3X Shares investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), NIO (nio), Direxion Daily Semiconductors Bull 3x Shares (SOXL), Tesla (TSLA) and Costco Wholesale (COST).

Industry, Sector and Symbol

• Stock Exchange: CNSX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CNSX:CURE
• CIK: N/A
• Web: www.biocuretech.com
• Phone: 604-609-7149
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A